Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025.
The company said it achieved the goal of $4 bln in cost savings through 2024 and anticipates an additional $500 mln in savings in 2025, from the ongoing cost realignment programPfizer continues to expect fiscal 2024 revenue in the range of $61 billion to $64 billion and confirmed its full-year adjusted EPS guidance of $2.75-2.95For fiscal 2025, the management expects revenue to be in the range of $61 billion to $64 billion and adjusted EPS between $2.80 and $3.00It is looking for adjusted EPS operational growth of 10-18% for FY25, from the midpoint of the 2024 guidance after adjusting for non-recurring itemsPhase I of the company’s manufacturing optimization program is on track to deliver initial net cost savings in the latter part of 2025, towards the goal of improving gross margin performanceAdjusted SI&A expense is expected to be in the range of $13.3 to $14.3 billion in FY25, and adjusted R&D expenses between $10.7 billion and $11.7 billion
The post Pfizer (PFE) reaffirms FY24 forecast; povides FY25 guidance first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
